Froning K J, Leaver-Fay A, Wu X, Phan S, Gao L, Huang F, Pustilnik A, Bacica M, Houlihan K, Chai Q, Fitchett J R, Hendle J, Kuhlman B, Demarest S J
Eli Lilly Biotechnology Center, 10300 Campus Point Drive, San Diego, California, 92121.
Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Protein Sci. 2017 Oct;26(10):2021-2038. doi: 10.1002/pro.3240. Epub 2017 Jul 31.
The use of bispecific antibodies (BsAbs) to treat human diseases is on the rise. Increasingly complex and powerful therapeutic mechanisms made possible by BsAbs are spurring innovation of novel BsAb formats and methods for their production. The long-lived in vivo pharmacokinetics, optimal biophysical properties and potential effector functions of natural IgG monoclonal (and monospecific) antibodies has resulted in a push to generate fully IgG BsAb formats with the same quaternary structure as monoclonal IgGs. The production of fully IgG BsAbs is challenging because of the highly heterogeneous pairing of heavy chains (HCs) and light chains (LCs) when produced in mammalian cells with two IgG HCs and two LCs. A solution to the HC heterodimerization aspect of IgG BsAb production was first discovered two decades ago; however, addressing the LC mispairing issue has remained intractable until recently. Here, we use computational and rational engineering to develop novel designs to the HC/LC pairing issue, and particularly for κ LCs. Crystal structures of these designs highlight the interactions that provide HC/LC specificity. We produce and characterize multiple fully IgG BsAbs using these novel designs. We demonstrate the importance of specificity engineering in both the variable and constant domains to achieve robust HC/LC specificity within all the BsAbs. These solutions facilitate the production of fully IgG BsAbs for clinical use.
双特异性抗体(BsAbs)在人类疾病治疗中的应用正在增加。BsAbs所带来的日益复杂且强大的治疗机制正在推动新型BsAb形式及其生产方法的创新。天然IgG单克隆(和单特异性)抗体具有长寿命的体内药代动力学、最佳生物物理特性和潜在效应功能,这促使人们努力生成具有与单克隆IgGs相同四级结构的全IgG BsAb形式。由于在哺乳动物细胞中用两条IgG重链(HCs)和两条轻链(LCs)生产时,重链和轻链存在高度异质配对,全IgG BsAbs的生产具有挑战性。二十年前首次发现了解决IgG BsAb生产中HC异二聚化问题的方法;然而,直到最近,解决LC错配问题仍然难以解决。在这里,我们使用计算和理性工程来开发针对HC/LC配对问题的新设计,特别是针对κ轻链。这些设计的晶体结构突出了提供HC/LC特异性的相互作用。我们使用这些新设计生产并表征了多种全IgG BsAbs。我们证明了在可变域和恒定域中进行特异性工程对于在所有BsAbs中实现强大的HC/LC特异性的重要性。这些解决方案有助于生产用于临床的全IgG BsAbs。